Cystic fibrosis.

Lancet. 388: 2519-2531

Immune responses in cystic fibrosis: are they intrinsically defective?.

Am J Respir Cell Mol Biol. 46: 715-722Tousson A Van Tine BA Naren AP Shaw GM Schwiebert LM

Characterization of CFTR expression and chloride channel activity in human endothelia.

Am J Physiol. 275: C1555-C1564Vizzardi E Sciatti E Bonadei I Cani DS Menotti E Prati F Dallapellegrina L Metra M Berlendis M Poli P Padoan R

Macro- and microvascular functions in cystic fibrosis adults without cardiovascular risk factors: A case-control study.

Monaldi Arch Chest Dis. : 89Bano–Rodrigo A Salcedo–Posadas A Villa–Asensi JR Tamariz–Martel A Lopez–Neyra A Blanco–Iglesias E

Right ventricular dysfunction in adolescents with mild cystic fibrosis.

J Cyst Fibros. 11: 274-280Bright–Thomas RJ Webb AK

The heart in cystic fibrosis.

J R Soc Med. 95: 2-10

Cystic fibrosis complicated by cor pulmonale: the first case report in Taiwan.

Pediatr Neonatol. 59: 310-311Burgel PR Bellis G Olesen HV Viviani L Zolin A Blasi F Elborn JS EETFoPoCfAwCFi Europe

Future trends in cystic fibrosis demography in 34 European countries.

Eur Respir J. 46: 133-141Heijerman HGM McKone EF Downey DG Van Braeckel E Rowe SM Tullis E Mall MA Welter JJ Ramsey BW McKee CM Marigowda G Moskowitz SM Waltz D Sosnay PR Simard C Ahluwalia N Xuan F Zhang Y Taylor–Cousar JL McCoy KS

Group VXT: Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.

Lancet. 394: 1940-1948Middleton PG Mall MA Drevinek P Lands LC McKone EF Polineni D Ramsey BW Taylor–Cousar JL Tullis E Vermeulen F Marigowda G McKee CM Moskowitz SM Nair N Savage J Simard C Tian S Waltz D Xuan F Rowe SM Jain R Group VXS

Elexacaftor–Tezacaftor–Ivacaftor for cystic fibrosis with a single Phe508del Allele.

N Engl J Med. 381: 1809-1819Regard L Lafoeste H Martin C Chassagnon G Burgel PR

[Ageing with cystic fibrosis: Classical and emerging comorbidities in adults with cystic fibrosis].

Rev Pneumol Clin. 74: 279-291Nowak JK Szczepanik M Wojsyk–Banaszak I Madry E Wykretowicz A Krzyzanowska–Jankowska P Drzymala–Czyz S Nowicka A Pogorzelski A Sapiejka E Skorupa W Miskiewicz–Chotnicka A Lisowska A Walkowiak J

Cystic fibrosis dyslipidaemia: a cross–sectional study.

J Cyst Fibros. 18: 566-571Jiang K Jiao S Vitko M Darrah R Flask CA Hodges CA Yu X

The impact of cystic fibrosis transmembrane regulator disruption on cardiac function and stress response.

J Cyst Fibros. 15: 34-42Duan D Ye L Britton F Miller LJ Yamazaki J Horowitz B Hume JR

Purinoceptor-coupled Cl- channels in mouse heart: a novel, alternative pathway for CFTR regulation.

J Physiol. 521: 43-56Warth JD Collier ML Hart P Geary Y Gelband CH Chapman T Horowitz B Hume JR

CFTR chloride channels in human and simian heart.

Cardiovasc Res. 31: 615-624Sellers ZM Kovacs A Weinheimer CJ Best PM

Left ventricular and aortic dysfunction in cystic fibrosis mice.

J Cyst Fibros. 12: 517-524Sellers ZM McGlocklin L Brasch A

Strain rate echocardiography uncovers subclinical left ventricular dysfunction in cystic fibrosis.

J Cyst Fibros. 14: 654-660Eising JB van der Ent CK Teske AJ Vanderschuren MM Uiterwaal C Meijboom FJ

Young patients with cystic fibrosis demonstrate subtle alterations of the cardiovascular system.

J Cyst Fibros. Ozcelik N Shell R Holtzlander M Cua C

Decreased right ventricular function in healthy pediatric cystic fibrosis patients versus non-cystic fibrosis patients.

Pediatr Cardiol. 34: 159-164Koelling TM Dec GW Ginns LC Semigran MJ

Left ventricular diastolic function in patients with advanced cystic fibrosis.

Chest. 123: 1488-1494Labombarda F Saloux E Brouard J Bergot E Milliez P

Heart involvement in cystic fibrosis: a specific cystic fibrosis-related myocardial changes?.

Respir Med. 118: 31-38Florea VG Florea ND Sharma R Coats AJ Gibson DG Hodson ME Henein MY

Right ventricular dysfunction in adult severe cystic fibrosis.

Chest. 118: 1063-1068De Wolf D Franken P Piepsz A Dab I

Left ventricular perfusion deficit in patients with cystic fibrosis.

Pediatr Pulmonol. 25: 93-98Sullivan MM Moss RB Hindi RD Lewiston NJ

Supraventricular tachycardia in patients with cystic fibrosis.

Chest. 90: 239-242Florencio R Fregonezi G Brilhante S Borghi–Silva A Dias F Resqueti V

Heart rate variability at rest and after the 6–minute walk test (6MWT) in children with cystic fibrosis.

Braz J Phys Ther. 17: 419-426D'Angelo AM Chan EG Hayanga JW Odell DD Pilewski J Crespo M Morrell M Shigemura N Luketich J Bermudez C Althouse AD D'Cunha J

Atrial arrhythmias after lung transplantation: incidence and risk factors in 652 lung transplant recipients.

J Thorac Cardiovasc Surg. 152: 901-909See VY Roberts–Thomson KC Stevenson WG Camp PC Koplan BA

Atrial arrhythmias after lung transplantation: epidemiology, mechanisms at electrophysiology study, and outcomes.

Circ Arrhythm Electrophysiol. 2: 504-510Avedissian SN Rhodes NJ Ng TMH Rao AP Beringer PM

The potential for qt interval prolongation with chronic azithromycin therapy in adult cystic fibrosis patients.

Pharmacotherapy. 39: 718-723

Cardiotoxicity of fluoroquinolones.

J Antimicrob Chemother. 49: 593-596Costantino S Paneni F Cosentino F

Ageing, metabolism and cardiovascular disease.

J Physiol. 594: 2061-2073Robert R Savineau JP Norez C Becq F Guibert C

Expression and function of cystic fibrosis transmembrane conductance regulator in rat intrapulmonary arteries.

Eur Respir J. 30: 857-864Vizzardi E Sciatti E Bonadei I Menotti E Prati F Scodro M Dallapellegrina L Berlendis M Poli P Padoan R Metra M

Elastic aortic properties in cystic fibrosis adults without cardiovascular risk factors: a case-control study.

Echocardiography. 36: 1118-1122Zouk AN Gulati S Xing D Wille KM Rowe SM Wells JM

Pulmonary artery enlargement is associated with pulmonary hypertension and decreased survival in severe cystic fibrosis: a cohort study.

PLoS One. 15e0229173

Prognostic significance of pulmonary hypertension in patients with cystic fibrosis: a systematic review and meta-analysis.

Medicine (Baltimore). 97: e9708

Pulmonary hypertension survival effects and treatment options in cystic fibrosis.

Curr Opin Pulm Med. 19: 652-661

Pulmonary artery hypertension: an underrated disease manifestation in cystic fibrosis?.

Lancet Respir Med. 4: 596-598Galie N Humbert M Vachiery JL Gibbs S Lang I Torbicki A Simonneau G Peacock A Vonk Noordegraaf A Beghetti M Ghofrani A Gomez Sanchez MA Hansmann G Klepetko W Lancellotti P Matucci M McDonagh T Pierard LA Trindade PT Zompatori M 2015 Hoeper M:

ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (ESC) and the European respiratory society (ERS): endorsed by: association for european paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT).

Eur Respir J. 46: 903-975Augustine DX Coates–Bradshaw LD Willis J Harkness A Ring L Grapsa J Coghlan G Kaye N Oxborough D Robinson S Sandoval J Rana BS Siva A Nihoyannopoulos P Howard LS Fox K Bhattacharyya S Sharma V Steeds RP Mathew T

Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography.

Echo Res Pract. 5 ()Goldring RM Fishman AP Turino GM Cohen HI Denning CR Andersen DH

Pulmonary hypertension and cor pulmonale in cystic fibrosis of the pancreas.

J Pediatr. 65: 501-524Sciatti E Vizzardi E Bonadei I Valentini F Menotti E Prati F Dallapellegrina L Berlendis M Poli P Padoan R Metra M

Focus on echocardiographic right ventricular strain analysis in cystic fibrosis adults without cardiovascular risk factors: a case-control study.

Intern Emerg Med. 14: 1279-1285Dorfmuller P Perros F Balabanian K Humbert M

Inflammation in pulmonary arterial hypertension.

Eur Respir J. 22: 358-363Goldenberg NM Steinberg BE

Inflammation drives pulmonary arterial hypertension.

Anesthesiology. 130: 820-821Hall S Brogan P Haworth SG Klein N

Contribution of inflammation to the pathology of idiopathic pulmonary arterial hypertension in children.

Thorax. 64: 778-783Lan NSH Massam BD Kulkarni SS Lang CC

Pulmonary arterial hypertension: pathophysiology and treatment.

Diseases. : 6Elizur A Cannon CL Ferkol TW

Airway inflammation in cystic fibrosis.

Chest. 133: 489-495Poore S Berry B Eidson D McKie KT Harris RA

Evidence of vascular endothelial dysfunction in young patients with cystic fibrosis.

Chest. 143: 939-945Noe J Petrusca D Rush N Deng P VanDemark M Berdyshev E Gu Y Smith P Schweitzer K Pilewsky J Natarajan V Xu Z Obukhov AG Petrache I

CFTR regulation of intracellular pH and ceramides is required for lung endothelial cell apoptosis.

Am J Respir Cell Mol Biol. 41: 314-323Verhaeghe C Tabruyn SP Oury C Bours V Griffioen AW

Intrinsic pro–angiogenic status of cystic fibrosis airway epithelial cells.

Biochem Biophys Res Commun. 356: 745-749Wells JM Farris RF Gosdin TA Dransfield MT Wood ME Bell SC Rowe SM

Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study.

Lancet Respir Med. 4: 636-645Efrati O Harash O Rivlin J Bibi H Meir MZ Blau H Mussaffi H Barak A Levy I Vilozni D Kerem E

Modan–Moses D: Hemoptysis in Israeli CF patients–prevalence, treatment, and clinical characteristics.

J Cyst Fibros. 7: 301-306Barben J Robertson D Olinsky A Ditchfield M

Bronchial artery embolization for hemoptysis in young patients with cystic fibrosis.

Radiology. 224: 124-130Monroe EJ Pierce DB Ingraham CR Johnson GE Shivaram GM Valji K

An interventionalist's guide to hemoptysis in cystic fibrosis.

Radiographics. 38: 624-641Walker CM Rosado–de–Christenson ML Martinez–Jimenez S Kunin JR Wible BC

Bronchial arteries: anatomy, function, hypertrophy, and anomalies.

Radiographics. 35: 32-49Wand O Guber E Guber A Epstein Shochet G Israeli–Shani L Shitrit D

Inhaled tranexamic acid for hemoptysis treatment: a randomized controlled trial.

Chest. 154: 1379-1384Cystic Fibrosis Foundation

Patient Registry Annual Data Report 2019.

www.cff.org, Bethesda, MDBatra K Chamarthy MR Reddick M Roda MS Wait M Kalva SP

Diagnosis and interventions of vascular complications in lung transplant.

Cardiovasc Diagn Ther. 8: 378-386Denton EJ Rischin A McGiffin D Williams TJ Paraskeva MA Westall GP Snell G

Refractory pulmonary edema caused by late pulmonary vein thrombosis after lung transplantation: a rare adverse event.

Ann Thorac Surg. 102 ()Miyaji K Nakamura K Maruo T Morita H Saito H Emori T Goto K Date H Ohe T

Effect of a kink in unilateral pulmonary artery anastomosis on velocities of blood flow through bilateral pulmonary vein anastomoses in living-donor lobar lung transplantation.

J Am Soc Echocardiogr. 17: 998-999Anaya–Ayala JE Loebe M Davies MG

Endovascular management of early lung transplant–related anastomotic pulmonary artery stenosis.

J Vasc Interv Radiol. 26: 878-882Dai DW Garber B Weigt SS Worswick S Kubak BM Lynch 3rd, JP Shino MY DerHovanessian A Saggar R Ross DJ Sayah DM

Pulmonary allograft versus host disease.

Transplant Direct. 3: e333

Cardiovascular toxicities of immunosuppressive agents.

Am J Transplant. 2: 807-818Dogan P Grbovic E Inci S Bayraktar F Cagli K

Azathioprine-induced atrial fibrillation.

Intractable Rare Dis Res. 4: 207-209

Immunosuppression for lung transplantation.

Proc Am Thorac Soc. 6: 47-53Skolnik K Levy RD Wilcox PG Quon BS

Coronary artery disease in cystic fibrosis: An emerging concern?.

J Cyst Fibros. 15 ()

Ischaemic heart disease––a new issue in cystic fibrosis?.

J R Soc Med. 103: S44-S48Reverri EJ Morrissey BM Cross CE Steinberg FM

Inflammation, oxidative stress, and cardiovascular disease risk factors in adults with cystic fibrosis.

Free Radic Biol Med. 76: 261-277Figueroa V Milla C Parks EJ Schwarzenberg SJ Moran A

Abnormal lipid concentrations in cystic fibrosis.

Am J Clin Nutr. 75: 1005-1011Rhodes B Nash EF Tullis E Pencharz PB Brotherwood M Dupuis A Stephenson A

Prevalence of dyslipidemia in adults with cystic fibrosis.

J Cyst Fibros. 9: 24-28Zemanick ET Wagner BD Robertson CE Stevens MJ Szefler SJ Accurso FJ Sagel SD Harris JK

Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods.

Ann Am Thorac Soc. 12: 221-229Hart NJ Aramandla R Poffenberger G Fayolle C Thames AH Bautista A Spigelman AF Babon JAB DeNicola ME Dadi PK Bush WS Balamurugan AN Brissova M Dai C Prasad N Bottino R Jacobson DA Drumm ML Kent SC MacDonald PE Powers AC

Cystic fibrosis–related diabetes is caused by islet loss and inflammation.

JCI Insight. : 3Gangell C Gard S Douglas T Park J de Klerk N Keil T Brennan S Ranganathan S Robins–Browne R Sly PD Arest CF

Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis.

Clin Infect Dis. 53: 425-432Sagel SD Sontag MK Accurso FJ

Relationship between antimicrobial proteins and airway inflammation and infection in cystic fibrosis.

Pediatr Pulmonol. 44: 402-409Sagel SD Chmiel JF Konstan MW

Sputum biomarkers of inflammation in cystic fibrosis lung disease.

Proc Am Thorac Soc. 4: 406-417

Inflammation in atherosclerosis.

Arterioscler Thromb Vasc Biol. 32: 2045-2051Sagel SD Thompson V Chmiel JF Montgomery GS Nasr SZ Perkett E Saavedra MT Slovis B Anthony MM Emmett P Heltshe SL

Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation.

Ann Am Thorac Soc. 12: 708-717Bonfield TL Panuska JR Konstan MW Hilliard KA Hilliard JB Ghnaim H Berger M

Inflammatory cytokines in cystic fibrosis lungs.

Am J Respir Crit Care Med. 152: 2111-2118

The role of TNF in cardiovascular disease.

Pharmacol Res. 40: 97-105Greally P Hussein MJ Cook AJ Sampson AP Piper PJ Price JF

Sputum tumour necrosis factor–alpha and leukotriene concentrations in cystic fibrosis.

Arch Dis Child. 68: 389-392Mitola S Sorbello V Ponte E Copreni E Mascia C Bardessono M Goia M Biasi F Conese M Poli G Bussolino F De Rose V

Tumor necrosis factor–alpha in airway secretions from cystic fibrosis patients upregulate endothelial adhesion molecules and induce airway epithelial cell apoptosis: implications for cystic fibrosis lung disease.

Int J Immunopathol Pharmacol. 21: 851-865

Interleukin–6 and cardiovascular diseases.

Jpn Heart J. 45: 183-193Ordonez CL Henig NR Mayer–Hamblett N Accurso FJ Burns JL Chmiel JF Daines CL Gibson RL McNamara S Retsch–Bogart GZ Zeitlin PL Aitken ML

Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.

Am J Respir Crit Care Med. 168: 1471-1475Schumacher SM Naga Prasad SV

Tumor necrosis factor-alpha in heart failure: an updated review.

Curr Cardiol Rep. 20: 117Hunt WR Helfman BR McCarty NA Hansen JM

Advanced glycation end products are elevated in cystic fibrosis-related diabetes and correlate with worse lung function.

J Cyst Fibros. 15: 681-688Hameed S Jaffe A Verge CF

Advances in the detection and management of cystic fibrosis related diabetes.

Curr Opin Pediatr. 27: 525-533

Cystic fibrosis related diabetes.

Curr Diab Rep. 14: 511Olesen HV Drevinek P Gulmans VA Hatziagorou E Jung A Mei–Zahav M Stojnic N Thomas M Zolin A Group ES

Cystic fibrosis related diabetes in Europe: Prevalence, risk factors and outcome; Olesen et al..

J Cyst Fibros. Granados A Chan CL Ode KL Moheet A Moran A Holl R

Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis.

J Cyst Fibros. 18 ()

Cystic Fibrosis F.

: 1-85Kelly A De Leon DD Sheikh S Camburn D Kubrak C Peleckis AJ Stefanovski D Hadjiliadis D Rickels MR Rubenstein RC

Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy.

Am J Respir Crit Care Med. 199: 342-351Thomassen JC Mueller MI Alejandre Alcazar MA Rietschel E van Koningsbruggen–Rietschel S

Effect of Lumacaftor/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients.

J Cyst Fibros. 17: 271-275

Premature vascular ageing in cystic fibrosis.

Eur Respir J. 34: 1217-1218Rodriguez–Miguelez P Thomas J Seigler N Crandall R McKie KT Forseen C Harris RA

Evidence of microvascular dysfunction in patients with cystic fibrosis.

Am J Physiol Heart Circ Physiol. 310: H1479-H1485Cook DP Rector MV Bouzek DC Michalski AS Gansemer ND Reznikov LR Li X Stroik MR Ostedgaard LS Abou Alaiwa MH Thompson MA Prakash YS Krishnan R Meyerholz DK Seow CY Stoltz DA

Cystic fibrosis transmembrane conductance regulator in sarcoplasmic reticulum of airway smooth muscle. Implications for airway contractility.

Am J Respir Crit Care Med. 193: 417-426Hubner CA Schroeder BC Ehmke H

Regulation of vascular tone and arterial blood pressure: role of chloride transport in vascular smooth muscle.

Pflugers Arch. 467: 605-614Peters W Kusche–Vihrog K Oberleithner H Schillers H

Cystic fibrosis transmembrane conductance regulator is involved in polyphenol–induced swelling of the endothelial glycocalyx.

Nanomedicine. 11: 1521-1530Totani L Plebani R Piccoli A Di Silvestre S Lanuti P Recchiuti A Cianci E Dell'Elba G Sacchetti S Patruno S Guarnieri S Mariggio MA Mari VC Anile M Venuta F Del Porto P Moretti P Prioletta M Mucilli F Marchisio M Pandolfi A Evangelista V Romano M

Mechanisms of endothelial cell dysfunction in cystic fibrosis.

Biochim Biophys Acta. 1863: 3243-3253Hull JH Garrod R Ho TB Knight RK Cockcroft JR Shale DJ Bolton CE

Increased augmentation index in patients with cystic fibrosis.

Eur Respir J. 34: 1322-1328Hull JH Garrod R Ho TB Knight RK Cockcroft JR Shale DJ Bolton CE

Dynamic vascular changes following intravenous antibiotics in patients with cystic fibrosis.

J Cyst Fibros. 12: 125-129Buehler T Steinmann M Singer F Regamey N Casaulta C Schoeni MH Simonetti GD

Increased arterial stiffness in children with cystic fibrosis.

Eur Respir J. 39: 1536-1537Schwarzenberg SJ Thomas W Olsen TW Grover T Walk D Milla C Moran A

Microvascular complications in cystic fibrosis–related diabetes.

Diabetes Care. 30: 1056-1061

Low blood pressure in young adults with cystic fibrosis: an effect of chronic salt loss in sweat?.

Ann Intern Med.